<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03003806</url>
  </required_header>
  <id_info>
    <org_study_id>RMC072016ctil</org_study_id>
    <nct_id>NCT03003806</nct_id>
  </id_info>
  <brief_title>Evaluation of the Dreamed Advisor Pro for Automated Insulin Pump Setting Adjustments in Children and Adolescents With Type 1 Diabetes- The Advice4U Pro Study</brief_title>
  <acronym>Advice4U</acronym>
  <official_title>Evaluation of the Dreamed Advisor Pro for Automated Insulin Pump Setting Adjustments in Children and Adolescents With Type 1 Diabetes- Open Label, Parallel , Randomized, Controlled Multicenter Study-The Advice4U Pro Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rabin Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>DreaMed</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Leona M. and Harry B. Helmsley Charitable Trust</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Rabin Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The DreaMed Advisor Pro is a software which automatically analyses treatment information,
      learns patient's needs and accordingly suggests adjustments in insulin dosing. The DreaMed
      Advisor Pro uses information gathered from glucose monitoring (sensor readings or capillary
      blood glucose measurements), insulin dosing and meal data during daily routine home care.
      Following a 5-minute data collection and analysis, the algorithm learns and suggests
      pump-setting changes for optimization of glucose control

      The algorithm is designed as an advisory tool and has three main components:

        1. A statistical analysis of the insulin pump and sensor data: insulin delivery,
           bolus-calculator rate of use, sensor glucose variables, hypoglycemic and hyperglycemia
           patterns.

        2. Practical recommendations, alert messages based on aforementioned data

        3. Recommendation for new insulin pump settings: including basal intervals and rate,
           different carbohydrate ratio according to time of day, correction factor and insulin
           sensitivity time.

      The main goal of the DreaMed Advisor Pro is to improve diabetes management for subjects with
      Type 1 Diabetes (T1D) by using an innovative Advisor to determine insulin dosing for pump
      users.

      The main objective of the proposed study is to evaluate the safety and efficacy of using the
      DreaMed Advisor Pro algorithm versus medical guided recommendation to determine insulin
      dosing for sub-optimal controlled subjects with type 1 diabetes using pump therapy.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 2, 2017</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of glucose readings within range of 70-180 mg/dl (3.9 to 10 mmol/l).</measure>
    <time_frame>Final visit (week 31)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of glucose readings below 54 mg/dl (3.3 mmol/l)</measure>
    <time_frame>Final visit (week 31)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>HbA1c</measure>
    <time_frame>Final visit (week 31)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of glucose readings below 70 mg/dl (3.9 mmol/L)</measure>
    <time_frame>Final visit (week 31)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of readings below 50 mg/dl (2.8 mmol/L)</measure>
    <time_frame>Final visit (week 31)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of readings above 180 mg/dl (10.0 mmol/L)</measure>
    <time_frame>Final visit (week 31)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of readings above 240 mg/dl (13.3 mmol/L)</measure>
    <time_frame>Final visit (week 31)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area above the curve of glucose glucose level of 180 mg/dl</measure>
    <time_frame>Final visit (week 31)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the curve of glucose level of 70 mg/dl</measure>
    <time_frame>Final visit (week 31)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean sensor blood glucose</measure>
    <time_frame>Final visit (week 31)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Glucose variability measured by Standard Deviation</measure>
    <time_frame>Final visit (week 31)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of recommendations for changes in settings per patient</measure>
    <time_frame>Final visit (week 31)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of recommendations for changes in settings per iteration</measure>
    <time_frame>Final visit (week 31)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of physician override Advisor recommendations</measure>
    <time_frame>Final visit (week 31)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients overrides of recommendation</measure>
    <time_frame>Final visit (week 31)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Estimated time duration needed for the physician to give its recommendations</measure>
    <time_frame>Final visit (week 31)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Device satisfaction questionaire</measure>
    <time_frame>Final visit (week 31)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Diabetes treatment satisfaction questionnaire</measure>
    <time_frame>Final visit (week 31)</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">112</enrollment>
  <condition>Type1 Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>DreaMed Advisor Pro</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Insulin pump settings (i.e, basal plan, correction factor, carbohydrate ratio and insulin activity time) will be adjusted using the DreaMed Advisor Pro</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group-medical guided recommendations</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Insulin pump settings (i.e, basal plan, correction factor, carbohydrate ratio and insulin activity time) will be adjusted by the medical team</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>DreaMed Advisor Pro</intervention_name>
    <description>Insulin pump settings (i.e, basal plan, correction factor, carbohydrate ratio and insulin activity time) will be adjusted using the DreaMed Advisor Pro</description>
    <arm_group_label>DreaMed Advisor Pro</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Medical guided recommendation</intervention_name>
    <description>Insulin pump settings (i.e, basal plan, correction factor, carbohydrate ratio and insulin activity time) will be adjusted by the medical team</description>
    <arm_group_label>Control group-medical guided recommendations</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subject with Type 1 diabetes (&gt;1yr since diagnosis)

          -  Age ≥ 10 years up to 21 years

          -  HbA1c at inclusion ≥ 7.0% and ≤ 10%

          -  Insulin infusion pump therapy: &quot;OmniPod®&quot; Insulin pump (insulet Corp., Bedford, &quot;MA&quot;,
             USA) or any Medtronic pump that is comparable with Glooko app for at least 4 months

          -  BMI Standard Deviation Score (SDS) - below the 97th percentile for age

          -  Patients willing to follow study instructions (at least 2 capillary blood glucose
             readings/day, use the bolus-calculator feature of the pump)

          -  Patient/ parents are required to have minimum computer skills and understanding of
             navigating the internet

          -  Patients willing to use dexcom sensor for the study duration

          -  Patients/ parents will have to have a smart phone (Apple, Android, Windows)

        Exclusion Criteria:

          -  An episode of diabetic ketoacidosis within the month prior to study entry

          -  Concomitant diseases/ treatment that influence metabolic control

          -  Any significant diseases /conditions including psychiatric disorders and substance
             abuse that in the opinion of the investigator is likely to affect the subject's
             ability to complete the study or compromise patient's safety,

          -  Participation in any other interventional study

          -  Known or suspected allergy to trial products such as adhesives, tapes, needles. An
             allergy to contrast medium, use of other active medical devices (such as pacemaker,
             ICD) and planned imaging examinations (such as MRI).

          -  Female subject who is pregnant or lactating planning to become pregnant within the
             planned study duration -Severe hypoglycemia six month prior to enrollment as defined
             by the American Diabetes Association (ADA) and Endocrine Society as follows: &quot;Severe
             hypoglycemia is an event requiring assistance of another person to actively administer
             carbohydrates, glucagon, or take other corrective actions&quot;. -

          -  Current use of the following medications: medications that are used to lower blood
             glucose such as Pramlintide, Metformin and GLP-1 analogs. Beta blockers,
             glucocorticoids and other medications, which in the judgment of the investigator would
             be a contraindication to participation in the study (Anticoagulant therapy e.g.
             Plavix, LMW heparin, Coumadin, Immunosuppressant therapy)

          -  Relevant severe organ disorders (diabetic nephropathy, diabetic retinopathy, diabetic
             foot syndrome) or any secondary disease or complication of diabetes mellitus

               -  Subject has unstable or rapidly progressive renal disease or is receiving
                  dialysis

               -  Subject has active proliferating retinopathy

               -  Active gastroparesis

          -  Patient suffers from an eating disorder
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>10 Years</minimum_age>
    <maximum_age>21 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Moshe Phillip, Prof</last_name>
    <phone>972-3-9253282</phone>
    <email>mosheph@clalit.org.il</email>
  </overall_contact>
  <location>
    <facility>
      <name>Barbara Davis Center for Childhood Diabetes</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045-6511</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Robert Slover, Prof</last_name>
    </contact>
    <investigator>
      <last_name>Robert Slover, Prof</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Yale University School of Medicine</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06520-8064</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Stuart Weinzimer, Prof</last_name>
    </contact>
    <investigator>
      <last_name>Stuart Weinzimer, Prof</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Florida College of Medicine</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32610</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Desmond Schatz, Prof</last_name>
    </contact>
    <investigator>
      <last_name>Desmond Schatz, Prof</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Joslin Diabetes Center, One Joslin Place</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Lori Laffel, Prof</last_name>
    </contact>
    <investigator>
      <last_name>Lori Laffel, Prof</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Diabetes -Zentrum fuer kinder und jugendliche</name>
      <address>
        <city>Hannover</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Thomas Danne, MD</last_name>
      <phone>+49 511 8115 3330</phone>
    </contact>
    <investigator>
      <last_name>Thomas Danne, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Schnider children's medical center</name>
      <address>
        <city>Petach-Tikva</city>
        <zip>49202</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Moshe Phillip, Professor</last_name>
      <phone>972-3-9253778</phone>
      <email>mosheph@clalit.org.il</email>
    </contact>
    <investigator>
      <last_name>Moshe Phillip, Prof</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Revital Nimri, Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Liat De Vries, Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Liora Lazar, Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Tal Oron, Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ariel Tenennbaum, Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Shlomit Shalitin, Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Alon Farfel, Dr</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Judit Nir, Dr</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Naama Fish, Dr</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sari Karpel, Dr</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Children's Hospital</name>
      <address>
        <city>Ljubljana</city>
        <country>Slovenia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Tadej Battelino, Prof</last_name>
      <phone>+386 1 5232 8353</phone>
      <email>tadej.battelino@mf.uni-lj.si</email>
    </contact>
    <investigator>
      <last_name>Tadej Battelino, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>Israel</country>
    <country>Slovenia</country>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 22, 2016</study_first_submitted>
  <study_first_submitted_qc>December 22, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 28, 2016</study_first_posted>
  <last_update_submitted>November 22, 2017</last_update_submitted>
  <last_update_submitted_qc>November 22, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 24, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Insulin pump treatment</keyword>
  <keyword>Type 1 diabetes</keyword>
  <keyword>Pump setting advisor</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin, Globin Zinc</mesh_term>
    <mesh_term>Insulin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

